<DOC>
	<DOCNO>NCT00325481</DOCNO>
	<brief_summary>To assess safety bivalent vaccine two new influenza virus reassortants healthy adult prior release trivalent vaccine ( FluMist ) containing .</brief_summary>
	<brief_title>Study To Evaluate Safety Bivalent Vaccine</brief_title>
	<detailed_description>This prospective , randomize , double blind , placebo-controlled release study enroll approximately 300 healthy adult 18-49 year age . Eligible subject randomly assign 4:1 fashion receive single dose bivalent vaccine placebo intranasal spray . This study conduct multiple site United States . Randomization stratify site .</detailed_description>
	<criteria>Male female , 18 49 year age ( yet reach 50th birthday ) time study vaccination Healthy medical history health assessment Sexually active female , unless surgically sterile least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral , implanted , injectable , transdermal contraceptive , IUD , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) least 30 day prior study vaccination , must agree continue use precaution least 90 day study vaccination ; subject must also negative serum urine pregnancy test within 14 day prior study vaccination ( screen study vaccination occur day ) day study vaccination prior randomization Sexually active male , unless surgically sterile , must use effective method birth control ( condom abstinence ) must agree continue use precaution least 30 day study vaccination Available telephone Written inform consent ( HIPAA authorization applicable ) obtain subject Ability understand comply requirement protocol , judge investigator Ability complete followup period 180 day study vaccination require protocol History hypersensitivity component vaccine , include egg egg protein History hypersensitivity gentamicin Any condition inactivate influenza vaccine indicate , include chronic disorder pulmonary cardiovascular system ( e.g. , asthma ) , chronic metabolic disease ( e.g. , diabetes mellitus ) , renal dysfunction , hemoglobinopathy require regular medical followup hospitalization precede year Acute febrile ( &gt; 100.0°F oral equivalent ) and/or clinically significant respiratory illness ( e.g. , cough sore throat ) within 14 day prior randomization Any known immunosuppressive condition immune deficiency disease , include HIV infection , ongoing immunosuppressive therapy History GuillainBarré syndrome Household contact severely immunocompromised ( e.g. , hematopoietic stem cell transplant recipient , period immunocompromised individual require care protective environment ) ; subject additionally avoid close contact severely immunocompromised individual least 21 day study vaccination Receipt investigational agent within 30 day prior randomization , expect receipt 180 day study vaccination ( use license agent indication list package insert permit ) Expected receipt antipyretic analgesic medication daily every day basis randomization 14 day study vaccination Note : A daily dose 81 mg aspirin prophylactic use consider contraindication enrollment . Administration intranasal medication within 14 day prior randomization , expect receipt 14 day study vaccination Nursing mother Employee research center , individual involve conduct study , family member individual Any condition ( e.g. , chronic cough , allergic rhinitis ) opinion investigator would interfere evaluation vaccine interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>